RxDoctor Payments Data

Rachel Flanagan

Medical · Camden, NJNPI 1164766192

Payments from drug & device makers

$2,223in general payments, 2019–2025

Across 38 payments — averaging $58.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$468
  • Teleflex LLC$465
  • Myriad Genetic Laboratories, Inc.$316
  • Medtronic$289
  • Calyxo, Inc.$146
  • Ambu Inc.$115
  • plus $424 from 11 others

What the payments were for

  • Food & beverage$2,223100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific7$468
Teleflex LLC6$465
Myriad Genetic Laboratories, Inc.4$316
Medtronic4$289
Calyxo, Inc.1$146
Ambu Inc.1$115
AstraZeneca1$90
Johnson & Johnson2$85
Intuitive Surgical2$63
180 Medical, Inc.2$37
Urogen Pharma, Inc.2$35
Convatec Inc.1$26
Axonics, Inc.1$24
Sumitomo Pharma America, Inc.1$18
Hollister Incorporated1$16
ABC Home Medical Supply, Inc.1$16
Astellas Pharma US Inc1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,223 in reported general payments places this provider in the 75th percentile of 573 medical providers in New Jersey.

See all medical providers in New Jersey

Medicare billing

Part B allowed, 2024
$10,561
Medicare patients
83
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron24$14,118
Tamsulosin Hcl228$3,557
Solifenacin Succinate62$1,630
Desmopressin Acetate15$1,065
Oxybutynin Chloride ErOxybutynin Chloride39$1,060
Finasteride60$888
Oxybutynin Chloride57$632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$15$14,11824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 573 medical providers in New Jersey.

Other medical in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →